Back to News

News > OncoCheckpoint: Comp ...

OncoCheckpoint: Companion DX for Cdc7 inhibitors

Oncologica has established the first comprehensive predictive test for Cdc7 inhibitors using its state of the art Next Generation Sequencing platform validated for the delivery of Oncologica’s precision oncology clinical services.

Our newly developed Cdc7 companion Dx “OncoCheckpoint” analyses the major signalling components of the DNA replication origin activation checkpoint for all activating/inactivating genetic aberrations that lead to loss of checkpoint control and therefore predictive of response to Cdc7 inhibitors.
The test has been specifically designed to use a DNA/RNA input extracted from routine formalin fixed paraffin wax embedded (FFPE) pathology biopsies/resection specimens so is ideally suited to support clinical trials and for use in routine clinical practice